<DOC>
	<DOCNO>NCT00973271</DOCNO>
	<brief_summary>The hypothesis study DCCR effective monotherapy combination statin lower triglyceride subject high triglyceride</brief_summary>
	<brief_title>Diazoxide Choline Controlled-Release Tablet ( DCCR ) Very High Triglycerides</brief_title>
	<detailed_description>Very high triglyceride risk pancreatitis . Studies show Diazoxide Choline potential effectively low triglyceride patient high triglyceride .</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Choline</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Diazoxide</mesh_term>
	<criteria>INCLUSION CRITERIA : Fasting triglyceride Difference Visit 3 ( 7 day prior Baseline Visit ) Visit 4 ( 3 day prior Baseline Visit ) ≤ 60 % ( compare high value Visit 3 Visit 4 ) Runin Triglycerides* ≥ 500 mg/dL &lt; 1500 mg/dL *Runin Triglyceride define average fasting triglyceride Visit 3 ( 7 day prior Baseline Visit ) Visit 4 ( 3 day prior Baseline Visit ) . Statin use Either Statinnaive Must statin Screening remain Runin/Washout Period throughout study Or Statintreated Must receive stable effective dose statin ≥ 3 month without significant side effect intolerance prior Screening Must willing switch 20 mg atorvastatin start Runin/Washout Period continue throughout study Medication washout All subject must willing undergo washout lipidlowering medication Fasting LDL cholesterol ≤ l60 mg/dL Screening Visit Visit 4 Glycemic status Fasting glucose &lt; 126 mg/dL Screening Visit HbA1c &lt; 6.5 % Screening Visit EXCLUSION CRITERIA : Medications : recent , current , anticipated Administration investigational drug within 1 month prior Screening Visit Thyroid hormone preparation within 1 month prior Screening Visit ( except subject stable dose replacement therapy least 1 month ) Thiazide diuretic within 2 week prior Screening Visit Discontinuation betablockers within 1 month prior Screening Visit plan discontinuation betablocker therapy Anticipated requirement use prohibit concomitant medication History allergic reaction significant intolerance : Diazoxide Thiazides Sulfonamides Fenofibrate fenofibric acid derivative Lifestyle change • Subjects intend change exercise habit , quit smoking and/or quit alcohol use initial 12week PlaceboControlled Treatment Period study Specific diagnose , medical condition history Known type I III hyperlipidemia Known type 1 DM Known type 2 DM Any clinically significant endocrine , cardiovascular , pulmonary , neurological , psychiatric , hepatic , gastrointestinal , hematological , renal , dermatological disease interfere assessment study medication , accord Investigator Specific laboratory test result • Any relevant biochemical abnormality interfere assessment study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>hypertriglyceridemia</keyword>
</DOC>